Some Big Year-End Dealmaking From SkyePharma

SkyePharma keeps its promise of profitability in 2002 by licensing its two most prominent pipeline candidates to Endo Pharmaceuticals. But now that the company has reached that benchmark, longer-term growth may require it to develop its own commercial capabilities.

Just when investors were getting jittery that SkyePharma PLC might not attain its well-publicized goal of reaching profitability in 2002, the drug delivery/product development company announced an end-of-year deal with Endo Pharmaceuticals Inc. that analysts think will almost certainly put it in the black [See Deal]. Endo licensed the US and Canadian rights to SkyePharma's highest profile development candidates: DepoMorphine, a Phase III sustained-release morphine injection for post-operative pain, and Propofol IDD-DTM, its Phase IIb nanoparticle formulation of the injected hospital anesthetic propofol. In exchange, SkyePharma received a $25 million (£15.3 million) upfront payment and could get another $95 million in regulatory and sales milestones.

SkyePharma, which will bear primary responsibility for continued development and manufacturing, is also entitled to a percentage of each product's...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo